Exalenz Bioscience Launches Study of Breath-Based Diagnostic Test Addressing the $2 Billion NASH Market Potential

– – Israel’s Exalenz Bioscience (TASE: EXEN), a developer and marketer of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced More...